FIA
CTXR icon

FNY Investment Advisers’s Citius Pharmaceuticals CTXR Stock Holding History

FNY Investment Advisers’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-600
Closed -$18K – 636
2023
Q2 		$18K Buy
+600
New +$19.7K 0.02% 254

Other funds holding CTXR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

FNY Investment Advisers's CTXR Position: Q3 2023 in Review

FNY Investment Advisers sold out of Citius Pharmaceuticals (CTXR) in Q3 2023, closing a stake of 600 shares — an estimated $18K sold.

FNY Investment Advisers first reported a position in CTXR in Q2 2023 and held it in 1 quarter. The position peaked at $18K in Q2 2023. 74 funds tracked by Wall St. Rank hold CTXR as of Q3 2023.

  • FNY Investment Advisers reported no remaining Citius Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • FNY Investment Advisers sold 600 Citius Pharmaceuticals shares in Q3 2023, an estimated $18K.
  • FNY Investment Advisers first reported a position in Citius Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • FNY Investment Advisers's Citius Pharmaceuticals position peaked at $18K in Q2 2023.
  • 74 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q3 2023.

Based on FNY Investment Advisers's 13F filing for Q3 2023, filed 10 Oct 2023.